Compare Ascendis Pharma A/S (ASND) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs ZIM Integrated Shipping Services Ltd — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while ZIM Integrated Shipping Services Ltd trades at $23.95 (market cap $2.89B). The key difference: Ascendis Pharma A/S is far larger — about 6.1× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 7.88% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ZIM | |
|---|---|---|
Market Cap | $17.74B | $2.89B |
Sector | Health | Industrials |
52-Week High | $277.18 | $29.27 |
52-Week Low | $163.32 | $12.44 |
Enterprise Value | $18.11B | $6.74B |
Dividend Yield | — | 7.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ZIM trades at $23.97, down 0.7% on the day, with a bearish technical signal from moving averages. The company reported a Q1 2026 net loss of $86 million, missing EPS expectations, though revenue pressure from lower freight rates may be offset by recent supply chain disruptions. Valuation metrics show a low P/S of 0.46 and P/B of 0.76, suggesting potential undervaluation relative to assets. Key developments include a pending merger with Hapag-Lloyd facing regulatory hurdles and a rival $4.5 billion takeover bid from Haim Sakal.
The outlook for ZIM is clouded by operational challenges and merger uncertainty, but current asset-based valuations provide a floor near $29–$30 per share. Investment opportunity exists if merger approvals proceed or freight rates rebound from Hormuz blockade effects. Primary risks include regulatory rejection of deals, sustained earnings pressure, and high debt-to-asset ratio of 0.71. Analyst consensus is split evenly between Hold and Sell with a $16.75 price target, indicating cautious sentiment amid speculative M&A dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
